ONC vs. RVMD: BeOne Medicines vs. Revolution Medicines Stock Comparison
How do BeOne Medicines (ONC) and Revolution Medicines (RVMD) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
BeOne Medicines (ONC) and Revolution Medicines (RVMD) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
Revolution Medicines (RVMD) trades as ordinary local shares, while BeOne Medicines (ONC) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.
| Profile Item | ONC | RVMD |
|---|---|---|
| Name | BeOne Medicines Ltd. American Depositary Shares | Revolution Medicines, Inc. |
| Country/Region | Switzerland | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 46.49 billion USD | 41.59 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | February 3, 2016 | February 13, 2020 |
| Security Type | ADR | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | ONC | RVMD |
|---|---|---|
| Total Return (1Y) | 30.59% | 224.80% |
| Total Return (3Y, Annualized) | 30.15% | 114.71% |
| Total Return (5Y, Annualized) | 2.48% | 43.47% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
Revolution Medicines (RVMD) has an aggressive beta of 1.42, indicating higher sensitivity to broad-market moves, while BeOne Medicines (ONC) is defensive at 0.59 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.
| Metric | ONC | RVMD |
|---|---|---|
| Volatility (1Y, Annualized) | 35.90% | 68.29% |
| Beta (5Y) | 0.59 | 1.42 |
| Max Drawdown (5Y) | -68.89% | -55.71% |
| Avg. Volume (3M) | 405.29K | 2.06M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | ONC | RVMD |
|---|---|---|
| Sharpe Ratio (1Y) | 0.73 | 3.23 |
| Sortino Ratio (1Y) | 1.15 | 6.92 |
Profitability
ROE (TTM)
Revolution Medicines (RVMD) reports a negative ROE of -93.56%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile BeOne Medicines (ONC) reports 18.40%, ranking against industry peers normally.
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
18.40%
- Max
- 109.18%
- ONC
- 18.40%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
RVMD
Pharmaceuticals, Biotechnology & Life Sciences industry group
-93.56%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- RVMD
- -93.56%
- Min
- -167.77%
Net Margin (TTM)
BeOne Medicines (ONC) at 13.86% retains a top-quartile share of revenue as profit, ahead of Revolution Medicines (RVMD) at 0.00%, which keeps about the industry-typical share.
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.86%
- Max
- 18.05%
- ONC
- 13.86%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
RVMD
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- Max
- 18.05%
- Q3
- 4.78%
- RVMD
- 0.00%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Revolution Medicines (RVMD) reports a negative operating margin of -188.88%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile BeOne Medicines (ONC) reports 22.15%, ranking against industry peers normally.
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
22.15%
- Max
- 83.12%
- ONC
- 22.15%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
RVMD
Pharmaceuticals, Biotechnology & Life Sciences industry group
-188.88%
- Max
- 83.12%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- RVMD
- -188.88%
- Min
- -207.40%
Profitability Metrics
| Metric | ONC | RVMD |
|---|---|---|
| ROE (TTM) | 18.40% | -93.56% |
| ROA (TTM) | 8.42% | -32.13% |
| Net Margin (TTM) | 13.86% | 0.00% |
| Operating Margin (TTM) | 22.15% | -188.88% |
| Gross Margin (TTM) | 89.39% | 0.00% |
Growth
Revenue Growth
Only one side can be read here: BeOne Medicines (ONC) reports revenue growth of 40.23%, ranked against its industry; Revolution Medicines (RVMD) has no revenue growth figure this period.
EPS Growth
Neither BeOne Medicines (ONC) nor Revolution Medicines (RVMD) reports a EPS growth value for this period, so a direct comparison isn't possible.
Growth Metrics
| Metric | ONC | RVMD |
|---|---|---|
| Revenue Growth (YoY) | 40.23% | -- |
| Revenue Growth (3Y CAGR) | 55.69% | -- |
| EPS Growth (YoY) | -- | -- |
| EPS Growth (3Y CAGR) | -- | -- |
Financial Strength
Current Ratio (MRQ)
Both BeOne Medicines (ONC) at 3.55 and Revolution Medicines (RVMD) at 8.36 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.55
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- ONC
- 3.55
- Q1
- 2.47
- Min
- 0.10
RVMD
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.36
- Max
- 25.13
- Q3
- 12.13
- RVMD
- 8.36
- Median
- 5.52
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Both BeOne Medicines (ONC) at 0.35 and Revolution Medicines (RVMD) at 0.50 fund their balance sheets with roughly industry-typical debt-to-equity mixes.
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.35
- Max
- 1.42
- Q3
- 0.65
- ONC
- 0.35
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
RVMD
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.50
- Max
- 1.42
- Q3
- 0.65
- RVMD
- 0.50
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | ONC | RVMD |
|---|---|---|
| Current Ratio (MRQ) | 3.55 | 8.36 |
| Debt / Equity (MRQ) | 0.35 | 0.50 |
| Net Debt / EBITDA | -2.80 | -- |
Dividends
Dividend Yield (TTM)
Neither BeOne Medicines (ONC) nor Revolution Medicines (RVMD) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ONC
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
RVMD
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- RVMD
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither BeOne Medicines (ONC) nor Revolution Medicines (RVMD) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ONC
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
RVMD
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- RVMD
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | ONC | RVMD |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
An earnings multiple is available for just one side: BeOne Medicines (ONC) trades at 52.17 times trailing earnings, ranked against its peers, while Revolution Medicines (RVMD) has no P/E ratio this period.
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
52.17
- Max
- 85.34
- ONC
- 52.17
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
RVMD
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- RVMD
- --
P/S Ratio (TTM)
BeOne Medicines (ONC) at 7.04 prices around its industry’s typical P/S ratio, while Revolution Medicines (RVMD) at 210.51 clears its benchmark range — RVMD looks notably rich on sales.
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.04
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- ONC
- 7.04
- Q1
- 3.01
- Min
- 0.01
RVMD
Pharmaceuticals, Biotechnology & Life Sciences industry group
210.51
- RVMD
- 210.51
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Both look rich against book: BeOne Medicines (ONC) at 7.98 sits in the upper P/B ratio quartile, and Revolution Medicines (RVMD) at 17.31 prices even higher, above its industry range.
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.98
- Max
- 13.53
- ONC
- 7.98
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
RVMD
Pharmaceuticals, Biotechnology & Life Sciences industry group
17.31
- RVMD
- 17.31
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | ONC | RVMD |
|---|---|---|
| P/E Ratio (TTM) | 52.17 | -- |
| P/S Ratio (TTM) | 7.04 | 210.51 |
| P/B Ratio (MRQ) | 7.98 | 17.31 |
| Free Cash Flow Yield (TTM) | 2.21% | -2.13% |